NCT00828932已完成1 期
An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.
研究概览
简要总结
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males or females aged between 18 and 75 years (inclusive)
- •Able to give signed informed consent
- •Hepatic function will fall into one of the following categories:
- •One-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: AST, ALT, alkaline phosphatase, total bilirubin)
- •One-third of patients will have mild impairment (Child-Pugh score 5-6)
- •One-third of patients will have moderate impairment (Child-Pugh score 7-9)
- •All subjects will have a BMI of 27-45 kg/m2, inclusive.
- •Eligible male and female patients must agree not to participate in a conception process
- •Considered to be in stable health in the opinion of the Investigator.
排除标准
- •Prior participation in any study of lorcaserin.
- •Clinically significant new illness in the 1 month before screening
- •Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
- •History of any of the following cardiovascular conditions:
- •Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening
- •Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
- •Unstable angina
- •Surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no less than 3 months prior to dosing
- •Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
- •Initiation of a new prescription medication within 1 month prior to screening.
- •Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
- •Use of SSRI's, SNRI's, and other medications must meet the required washout periods.
- •Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
研究组 & 干预措施
Lorcaserin 10mg
Experimental
干预措施: Lorcaserin (Drug)
结局指标
主要结局
The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function.
次要结局
- To evaluate the safety and tolerability of lorcaserin
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of AgePharmacokinetics in Obese AdolescentsNCT02022956Eisai Inc.8
已完成
1 期
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly SubjectsObesityNCT00828581Eisai Inc.24
已完成
1 期
Pharmacokinetic Properties of Lorcaserin in Subjects With Renal ImpairmentRenal ImpairmentNCT00828438Eisai Inc.40
已完成
1 期
A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy VolunteersHealthyNCT01718652Johnson & Johnson Pharmaceutical Research & Development, L.L.C.18
终止
1 期
Study to Evaluate Menses Induction in Women Administered ProellexAmenorrheaNCT00881608Repros Therapeutics Inc.11